Characterization of Cardiac Electrophysiology Including ECG-Analysis

Abstract

Rare diseases of cardiac arrhythmias are called channelopathies which represent clinically challenging task to cope with and are considered as unrestricted area for drug innovations. The development of more effective medications that increases quality of life and reduces symptom burden, hospitalizations, and mortality ruminate prudent action. Pathophysiological basis of cellular mechanisms of antiarrhythmic drug actions is still uncovered for interpretation of pharmacovigilance results. Current therapeutic control of arrhythmias is moreover driven by clinical and demographic characteristics of patient groups then to individual, patient-specific and/or phenotype or genotype features. Contemporary limitations of pharmaceutical understanding on cellular mechanisms for clinical pharmacodynamics is the future key to unlock vast possibilities of innovation in electrocardiography industry. Accurate measurement of electrocardiograms (ECG) is critical for effective diagnosis of patient’s cardiac functions. Detailed examination of filters’ effects on ECG accuracy, reproducibility and robustness covering a wide range of available commercial products can provide valuable information on the relationship between quality and effectiveness of filters, and assessments of patients’ cardiac functions. The fact that standard ECG device comprises several limitations when it comes to signal acquisition due to large ambient noise and inherent restrictions of technique applied, it is of utmost importance to modernize electrocardiography or at least to incorporate novel diagnostic techniques such as fragmented QRS (fQRS), heart rate variability (HRV), T peak-T end (TpTe), heart rate turbulence (HRT) and T wave alternans (TWA) that all have predictive value for pharmacovigilance.